載入中
MeiraGTx Holdings plc operates as a clinical-stage gene therapy company, dedicated to pioneering therapeutic solutions for individuals afflicted by serious illnesses. Its development efforts span a broad spectrum of conditions, encompassing ocular diseases like inherited forms of blindness, as well as xerostomia (dry mouth) that often follows radiation treatment for head and neck cancers. The company also targets various degenerative and neurodegenerative disorders, notably amyotrophic lateral sclerosis (ALS) and Parkinson's disease. Currently, several of its programs are in active clinical development, including Phase 1/2 trials for Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, radiation-induced Xerostomia, and Parkinson's. MeiraGTx is also preparing to commence a clinical program for xerostomia linked to Sjogren's syndrome and maintains preclinical initiatives for other neurodegenerative conditions. A key collaboration exists with Janssen Pharmaceuticals, Inc. to advance regulatable gene therapy treatments, leveraging MeiraGTx's proprietary riboswitch technology. Established in 2015, MeiraGTx Holdings plc is headquartered in New York, New York.
前收盤價
US$10.69
+US$0.19 · +1.81%
盤中時間採用ET。市場資料可能有所延遲。
MeiraGTx Holdings plc operates as a clinical-stage gene therapy company, dedicated to pioneering therapeutic solutions for individuals afflicted by serious illnesses. Its development efforts span a broad spectrum of conditions, encompassing ocular diseases like inherited forms of blindness, as well as xerostomia (dry mouth) that often follows radiation treatment for head and neck cancers. The company also targets various degenerative and neurodegenerative disorders, notably amyotrophic lateral sclerosis (ALS) and Parkinson's disease. Currently, several of its programs are in active clinical development, including Phase 1/2 trials for Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, radiation-induced Xerostomia, and Parkinson's. MeiraGTx is also preparing to commence a clinical program for xerostomia linked to Sjogren's syndrome and maintains preclinical initiatives for other neurodegenerative conditions. A key collaboration exists with Janssen Pharmaceuticals, Inc. to advance regulatable gene therapy treatments, leveraging MeiraGTx's proprietary riboswitch technology. Established in 2015, MeiraGTx Holdings plc is headquartered in New York, New York.
日內區間
目前US$10.69
52週區間
目前US$10.69
盤中時間採用ET。市場資料可能有所延遲。
MeiraGTx Holdings plc operates as a clinical-stage gene therapy company, dedicated to pioneering therapeutic solutions for individuals afflicted by serious illnesses. Its development efforts span a broad spectrum of conditions, encompassing ocular diseases like inherited forms of blindness, as well as xerostomia (dry mouth) that often follows radiation treatment for head and neck cancers. The company also targets various degenerative and neurodegenerative disorders, notably amyotrophic lateral sclerosis (ALS) and Parkinson's disease. Currently, several of its programs are in active clinical development, including Phase 1/2 trials for Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, radiation-induced Xerostomia, and Parkinson's. MeiraGTx is also preparing to commence a clinical program for xerostomia linked to Sjogren's syndrome and maintains preclinical initiatives for other neurodegenerative conditions. A key collaboration exists with Janssen Pharmaceuticals, Inc. to advance regulatable gene therapy treatments, leveraging MeiraGTx's proprietary riboswitch technology. Established in 2015, MeiraGTx Holdings plc is headquartered in New York, New York.
日內區間
目前US$10.69
52週區間
目前US$10.69
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 8139.1萬 USD | 3327.9萬 USD | 1401.7萬 USD | 1592萬 USD | 3770.1萬 USD |
| 銷貨成本 | 484.3萬 USD | 2379.1萬 USD | — | — | — |
| 毛利 | 7654.8萬 USD | 948.8萬 USD | 1401.7萬 USD | 1592萬 USD | 3770.1萬 USD |
| 研究與開發 | 1.3億 USD | 1.19億 USD | 1.04億 USD | 8572.5萬 USD | 6669.4萬 USD |
| 銷售、一般及管理費用 | 5289.7萬 USD | 5421.6萬 USD | 4729.3萬 USD | 4655萬 USD | 4376.5萬 USD |
| 營業費用 | 1.83億 USD | 1.74億 USD | 1.51億 USD | 1.32億 USD | 1.1億 USD |
| 利息收入 | 181.8萬 USD | 414.5萬 USD | 227.2萬 USD | 77.7萬 USD | 21.2萬 USD |
| 利息支出 | 1219.7萬 USD | 1327.2萬 USD | 1324.5萬 USD | 494.6萬 USD | 28.8萬 USD |
| 折舊和攤銷 | 1254.2萬 USD | 1282.8萬 USD | 1372.4萬 USD | 860.3萬 USD | 787.3萬 USD |
| 營業利益 | −1.06億 USD | −1.64億 USD | −1.37億 USD | −1.16億 USD | −7275.8萬 USD |
| 淨利 | −1.14億 USD | −1.48億 USD | −8402.7萬 USD | −1.3億 USD | −7956.1萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$21.00
上漲空間 96.45%報告持有此股票曝險的交易所交易基金。
iShares Russell 2000 ETFIWM1647.98萬0.02%787.4億 USD0.19%US$278.94+0.49%
First Trust Small Cap Growth AlphaDEX FundFYC664.94萬0.49%13.49億 USD0.70%US$115.36+1.35%
iShares Biotechnology ETFIBB592.55萬0.06%108.2億 USD0.44%US$206.49+3.00%
Vanguard Russell 2000 ETFVTWO477.41萬0.03%180億 USD0.06%US$112.66+0.50%
iShares Russell 2000 Growth ETFIWO456.12萬0.03%139.17億 USD0.24%US$356.78+0.94%
State Street SPDR S&P Kensho New Economies Composite ETFKOMP272.5萬0.10%26.06億 USD0.20%US$66.35+1.13%
First Trust Small Cap Core AlphaDEX FundFYX244.81萬0.18%13.4億 USD0.58%US$135.38+0.28%
Janus Henderson Small Cap Growth Alpha ETFJSML244.19萬0.68%3.61億 USD0.30%US$87.477+1.00%iShares Russell 2000 ETFIWMFirst Trust Small Cap Growth AlphaDEX FundFYCiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOiShares Russell 2000 Growth ETFIWOState Street SPDR S&P Kensho New Economies Composite ETFKOMPFirst Trust Small Cap Core AlphaDEX FundFYXJanus Henderson Small Cap Growth Alpha ETFJSMLAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
